Similar results have earlier been reported where significant association was observed between XRCC2 promoter polymorphism and oral cancer risk32, breast cancer risk33, thyroid cancer risk34 and bladder cancer risk35. This evidence concerns the gene XRCC2 and urinary bladder carcinoma.